Physician profile
Gene Terrezza
NPI 1295929933
$15,649.37
in general payments reported to CMS, 2019-2025
26 companies · $3,159 in 2025
The $3,159 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $499 · 2021: $1,479 · 2022: $1,666 · 2023: $2,626 · 2024: $4,014 · 2025: $3,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,691 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Travel and Lodging: $608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,690.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Travel and Lodging | $607.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,131.12 | 2019-2025 | Dailies Total1, Precision 1, Air Optix Color |
| Bausch & Lomb Americas INC. | $2,558.14 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $1,149.41 | 2019-2025 | Acuvue |
| Coopervision INC. | $983.77 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Notal Vision, INC. | $804.29 | 2023-2024 | Foresee Home |
| Allergan, INC. | $725.59 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $587.39 | 2019-2021 | |
| Glaukos Corporation | $551.20 | 2020-2025 | Kxl System (Not Refurbished), Ce-Marked Kxla System |
| Abbvie INC. | $474.46 | 2022-2025 | Vuity |
| Dompe US, INC. | $422.92 | 2023-2025 | Oxervate |
| Apellis Pharmaceuticals, INC. | $369.78 | 2023-2024 | Syfovre |
| Lkc Technologies, INC. | $359.75 | 2024-2025 | |
| Aerie Pharmaceuticals, INC. | $318.29 | 2019-2021 | |
| Oyster Point Pharma, INC. | $281.73 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $136.60 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $119.81 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $116.98 | 2025 | Xdemvy |
| Genentech USA, INC. | $114.75 | 2024 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $107.16 | 2022 | |
| Astellas Pharma US INC | $89.25 | 2025 | Izervay |
| Maculogix, INC. | $81.89 | 2019 | |
| Sun Pharmaceutical Industries INC. | $69.36 | 2023 | Cequa |
| Derma Sciences, INC. | $31.82 | 2019 | |
| Sight Sciences, INC. | $24.79 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.88 | 2020 | |
| Lombart Brothers, INC. | $16.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gene Terrezza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.